MVIR:STO
Medivir AB
1,48 SEK
arrow_downward
-1,59%(-0,024) 1 d.
13. 10., 13:03:02 GMT+2 · SEK
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre MVIR…
Otvoriť
1,50 SEK
Vysoká
1,51 SEK
Nízka
1,47 SEK
Trh. kap.
927,52 mil.
Priem. obj.
1,46 mil.
Objem
389,71 tis.
Max. za 52 týž.
2,88 SEK
Min. za 52 týž.
0,34 SEK
Výnosy na akciu
-0,37 SEK
Akcie v obehu
624,18 mil.
Počet zamestnancov
6
Otvoriť
1,50 SEK
Vysoká
1,51 SEK
Nízka
1,47 SEK
Trh. kap.
927,52 mil.
Priem. obj.
1,46 mil.
Objem
389,71 tis.
Max. za 52 týž.
2,88 SEK
Min. za 52 týž.
0,34 SEK
Výnosy na akciu
-0,37 SEK
Akcie v obehu
624,18 mil.
Počet zamestnancov
6
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
ChartMill
·
pred 23 minútami
TG Therapeutics (NASDAQ:TGTX) Pairs Strong Growth With a High-Quality Breakout Setup
FinancialContent
·
pred 45 minútami
Domino's (NASDAQ:DPZ) Surprises With Q3 2026 Sales
Modesto Bee
·
pred 20 minútami
S&P 500 futures muted as investors await big bank earnings; chip weakness weighs
Profil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Informácie o subjekte Medivir AB